EP0132948A1 - Biochemische Bestimmungsmethode und Testkasten zum Gebrauch hierfür - Google Patents

Biochemische Bestimmungsmethode und Testkasten zum Gebrauch hierfür Download PDF

Info

Publication number
EP0132948A1
EP0132948A1 EP84304328A EP84304328A EP0132948A1 EP 0132948 A1 EP0132948 A1 EP 0132948A1 EP 84304328 A EP84304328 A EP 84304328A EP 84304328 A EP84304328 A EP 84304328A EP 0132948 A1 EP0132948 A1 EP 0132948A1
Authority
EP
European Patent Office
Prior art keywords
antiligand
agent
ligand
bound
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP84304328A
Other languages
English (en)
French (fr)
Other versions
EP0132948B1 (de
Inventor
Axel Johannsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IQ Bio Ltd
Original Assignee
IQ Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IQ Bio Ltd filed Critical IQ Bio Ltd
Priority to AT84304328T priority Critical patent/ATE62751T1/de
Publication of EP0132948A1 publication Critical patent/EP0132948A1/de
Application granted granted Critical
Publication of EP0132948B1 publication Critical patent/EP0132948B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/825—Pretreatment for removal of interfering factors from sample
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/826—Additives, e.g. buffers, diluents, preservatives

Definitions

  • This invention relates to biochemical detection methods, in which a ligand is bound to a surface, and an antiligand becomes bound to the said ligand.
  • ligand and antiligand are used herein to denote a complimentary pair of substances which are capable of recognising the specific spatial and charge configuration of each other, and of binding specifically with each other.
  • ligands are, for example antigens, haptens, and the partners of cell and non-cell associated, non-antibody receptors.
  • antiligand includes, for example, antibodies and non-cell and cell-associated non-antibody receptors.
  • non-antibody” receptors as used herein includes non-antibody receptors obtained from natural sources, and those produced synthetically, or semi-synthetically, and also includes analogues thereof that are capable of binding to an appropriate partner. Simiarly, their respective partners may be obtained from natural sources, or may be synthetic, or semi-synthetic, or analogues of natural partners, provided that they are capable of binding to the appropriate receptor.
  • biochemical detection methods employ the interaction between a ligand and an antiligand to bring about the placement of the antiligand in a position where it may be detected by some signal generating means.
  • the ligand is bound to a surface by chemical (covalent linkage) or physiochemical (hydrophobic interaction, adsorption, ligand-antiligand interaction or the like) means and the antiligand is normally introduced in aqueous solution.
  • Antiligand present in the solution binds to the ligand. Separation of the solution from the surface will then leave antiligand bound with the surface (via its binding with the ligand).
  • An assay for the antiligand may then be carried out.
  • the assay is carried out with the antiligand bound to the surface, although sometimes it may be first unbound from the surface.
  • the signal generating means may take the form of so-called "enzyme linked immunoassay", radioimmunological, immunobioluminescent, or immunofluorescent methods.
  • enzyme linked immunoassay radioimmunological, immunobioluminescent, or immunofluorescent methods.
  • TWEEN 20 Trade Mark
  • sorbitan mono-laurate detergent a sorbitan mono-laurate detergent
  • so-callled “noise” can arise due to non-specific binding between various components present in the system. Examples are binding of the antiligand to various proteins present in the system, other than the ligand bound to the surface, binding of the antiligand to the wall of the vessel in which the method is carried out, and binding of the ligand bound to the surface of the vessel with the antiligand, in a non-specific way, ie. other than to its intended binding side.
  • Such non-specific binding within biochemical detection systems is particularly significant when the detection means employs an amplification system, for example the enzyme-linked system described above.
  • a biochemical detection method in which a ligand is bound to a surface, an aqueous solution containing an antiligand is brought into contact therewith whereby antiligand becomes bound to ligand, the aqueous solution is separated from the thus bound antiligand, and the antiligand is detected using a detection means associated therewith, characterised in that the surface is treated with at least one agent for limiting non-specific binding of either the ligand or the antiligand with other substances, which agent is
  • the surfactant containing an aromatic residue preferably contains a hydrophilic substituent containing at least 10 carbon atoms, more preferably at least 20 carbon atoms.
  • This hydrophilic substituent will contain hydrophilic groups such as ether linkages and/or hydroxyl groups. It is preferred that the hydrophilic substituent is an oxyethylene condensate, containing at least 20 oxyethylene residues.
  • Preferred surfactants of the type (i) are surfactants of the formula Ar-(OCH 2 CH 2 ) n -oA, wherein Ar is a phenyl group optionally substituted by one or more alkyl groups containing in total from 1 to 14 carbon atoms, n is from 20 to 100, and A is a hydrogen atom, or a methyl or ethyl group. Most preferably, Ar is a phenyl group substituted by an alkyl group containing from 4 to 12 carbon atoms, particularly a phenyl group substituted by an alkyl group containing 8 carbon atoms. A is preferably hydrogen. n preferably has a value of from 25 to 80, for example 40, 50, 60, or 70.
  • surfactants of this type may be represented as para-octyl-phenyl-(OCH 2 CH 2 ) n OH, wherein n is as described above.
  • a series of suitable surfactants of this kind are those sold under the designation TRITON X-405, X-705 etc., by the Sigma Chemical Company, the designations "405" and "705" indicating a mean ethoxy chain length of 40 and 70 respectively.
  • TRITON X-405 and X-705 have HLB ratio of 17.9 and 18.7 respectively (as defined by Griffin, W.C. (1949) J.Soc. Cosmet.Chem., 1, 311-316). It is particularly preferred that the aromatic-containing surfactants have an HLB ratio of at least 16, preferably at least 17, although it may be that other detergents having a structure as set forth above, but having a lower HLB number, are satisfactory.
  • the aromatic detergent is preferably used in an aqueous solution, preferably an aqueous buffer solution, in which the concentration of the detegent (i) is from 0.01% to 10%, more preferably from 0.05% to 1% by weight.
  • the agent of type (ii) for reducing non-specific binding is a zwitterionic surfactant, preferably one having one amino residue and one acidic residue, which may be for example a carboxylic, phosphoric, or sulphonic acid residue.
  • the zwitterionic surfactant will have one tertiary amino group, and one sulphonic acid group.
  • Suitable zwitterionic surfactants are ones of the formula R l R 2 NR 3 R 4 wherein R 1 and R 2 are each independently hydrogen or a C l -C 6 alkyl group, R 3 is a C 1 -C 6 alkyl group bearing an S0 3 substituent, and R 4 is a C 8 -C 2 2 alkyl group.
  • R 1 and R 2 are each methyl or ethyl, more preferably, methyl.
  • R 3 may be a C 2 -C 6 , preferably C 3 -C 4 , more preferably C 3 alkyl group, bearing an S0 3 H substituent group.
  • R 4 may be a C 10 to C 18 , preferably C 12 to C 16 , more preferably C 14 alkyl group.
  • R 1 and R 2 are each methyl
  • R 3 is CH 2 CH 2 CH 2 S0 3 H
  • R 4 is n-tetradodecyl.
  • a example of a suitable detergent of this kind is that sold under the designation SB-14 by Calbiochem.
  • the zwitterionic surfactant is preferred employed in the form of an aqueous, preferably buffered solution, in a concentration of from 0.01% to 10% preferably from 0.05% to 1% by weight.
  • the agent (iii) is a solution containing a salt of a polyvalent anion, in a concentration of at least 100mM. Suitable salts are any which do not interfere with the biochemical detection method being carried out, and ammonium sulphate has been found to be particularly useful.
  • the salt is employed in a concentration of at least 100mM, preferably from 200 to 800mM, more preferably from 300 to 600 mM, particularly about 400mM.
  • the zwitterionic surfactant has been found to be of particular value when the surface to which the ligand is bound is a cellulosic surface, such as cellulose nitrate or nitrocellulose. Furthermore, the use of a zwitterionic surfactant produces particularly great and surprising advantages when the method of this invention is adapted to the detection of nucleic acids.
  • a surfactant containing an aromatic residue and at least 20 oxyethylene residues are particularly pronounced when the surface to which the ligand is bound is a synthetic polymer (as opposed to a cellulosic material which is derived from a natural product), such as polystyrene, polyvinyl chloride, polyamide, polyester or the like, particularly when the surface is polystyrene.
  • the method of this invention is particularly useful when the antiligand is a phosphatase or a conjugate of a phosphatase.
  • the detection means may employ dephosphorylation of an aromatic phosphate such as para-nitrophenyl phosphate in a conventional manner.
  • an aromatic phosphate such as para-nitrophenyl phosphate
  • the method described in European Patent Specifications Nos. 82300714, 82304117, and U.S. Patent Specification No. 4446321 may be employed.
  • the detection of the antiligand may be carried out either directly or indirectly, for example by measuring the effect of the antiligand on a second ligand/antiligand interaction. Differencing techniques may also be used.
  • the invention provides a biochemical detection method in which a ligand is bound to a surface, an aqueous solution containing an antiligand which is a conjugate of a phosphatase is brought into contact therewith whereby the antiligand becomes bound to ligand, the aqueous solution is separated from the bound antiligand and the antiligand is detected by causing the dephosphorylation of a phosphate of a nicotinamide dinucleotide to produce nicotinamide dinucleotide which starts a cyclic chemical reaction whereby it and its reduced form are interconverted and a detectable change also occurs by operation,of said cyclic chemical reaction, wherein an agent for limiting non-specific binding of the type (i), (ii), or (iii) as described above is utilised.
  • an agent for limiting non-specific binding of the type (i), (ii), or (iii) as described above is utilised.
  • this invention is adapted to the detection of a substance from the human or other mammalian body, it is often advantageous to use a sandwich technique.
  • an antigen such as enzyme, protein, hormone, bacterial antigen, visual antigen or the like
  • the biological fluid such as blood, serum, urine or the like
  • immobilise the antigen suspected of being in said fluid therefrom by contacting the fluid with an antibody thereto which is bound to a surface.
  • the fluid is separated from the surface and the surface washed.
  • the antibody with the antigen then comprises the ligand referred to herein before which is bound to a surface.
  • the antibody employed may be a polyclonal antibody or a monoclonal antibody.
  • the fluid containing the antigen is added to a solution already in contact with the surface to which the ligand is bound.
  • the antiligand can thus consist of antigen bound to labelled antibody (for example anti- antigen labelled with phosphatase) or antigen alone in which case a new ligand is formed which can subsequently react with the anti-ligand labelled antibody.
  • the method of the invention may be carried out utilising a pre-prepared test kit, comprising a vessel containing a test liquid, having a surface to which a ligand is bound (preferably a multi-well test plate) and at least one further vessel containing a reagent solution.
  • a pre-prepared test kit comprising a vessel containing a test liquid, having a surface to which a ligand is bound (preferably a multi-well test plate) and at least one further vessel containing a reagent solution.
  • the agent for limiting non-specific binding may be incorporated within a solution in the kit, or may have been used to treat the surface of the first vessel before it is supplied.
  • a biological test kit comprising
  • the invention is illustrated in the following Examples, all of which relate generally to immunoassay methods, and a general indication of a method of carrying out immunoassay techniques will first be described.
  • Monoclonal antibodies against human chorionic gonadotrophin, (HCG), were obtained from Serono diagnostics (code 12/17 & 11/6).
  • Polystyrene microtitre plates (Nunc-immunoplate) were coated with antibody 11/6 by pipetting 0.10 ml of 5 mg/l solution in 200 mM sodium carbonate (pH 9.0) into each well of a plate, leaving overnight at room temperature, emptying the plate and washing 3 times by adding .25 ml of 0.5% bovine serum albumin (BSA), and 5% lactose, (pH 7.5). The plates were left to air dry before being used.
  • BSA bovine serum albumin
  • a conjugate of alkaline phosphatase and the second monoclonal antibody (Serono 12/17) was made by thiolating the antibody and subsequently reacting it with a maleimide derivative of the alkaline phosphatase. Unreacted alkaline phosphatase and antibody were removed by high pressure gel filtration (TSK column SW 4000).
  • the conjugate was diluted to a concentration of approximately 1 ng/ml in a test buffer, containing lOmM tris, (pH 7.5) lmM MgCl 2 , 0.1% sodium azide and 1% BSA. Standard HCG solutions containing 0 and 1 mIU/ml were also prepared, in the same buffer. The effects of salts, and detergents on an immunoassay for HCG were determined by including the components of interest in the conjugate solution. All determinations were performed in duplicate and the average of resulting measurements used in all calculations.
  • 0.075ml of conjugate were pipetted into coated wells of a microtitre plate followed by 0.025ml of 0 or 1 mIU HCG standard.
  • 0.075ml of test buffer without conjugate followed by 0.025ml of HCG standard were pipetted into wells for determination of reagent blank.
  • the plate was incubated at room temperature for 1 hour, the wells were emptied and washed four times with 0.25ml of test buffer.
  • Remaining alkaline phosphatase was measured as follows. 0.1 ml of O.lmM nicotinamide adenine dinucleotide phosphate, (NADP) in 50mM diethanolamine (pH 9.5) were added and after a further 20 min 0.20ml were added of a solution containing alcohol dehydrogenase, 0.2 mg/ml ; diaphorase 0.15mg/ml ; p-iodonitrotetrazolium violet, 0.55 mM; ethanol, 4% (v/v); sodium hydrogen phosphate buffer, 25mM pH 7.2. Colour development was stopped after a further 10 min by adding 0.050ml of 0.2M sulphuric acid. The absorbance of each well at 492nM (A492nm) was read in a Multiskan MC spectrophotometer through the well plate reader.
  • NADP O.lmM nicotinamide adenine dinucleotide phosphate, (
  • the signal in the assay is the difference in absorbance given by the wells originally containing the 0 and 1 mIU HCG standard, an conjugate solution.
  • the noise in the assay is the difference in absorbance between the 0 mIU and reagent blank.
  • This Example illustrates the effect of Triton X-405 and X-705 detergents in reducing non-specific binding of an alkaline phosphatase conjugate to a coated polystyrene test plate.
  • Bovine IgG was used to coat a polystyrene plate as above, but at concentration of two micrograms per ml in 50 mM carbonate buffer, at pH 9.0, for 45 minutes. The plate was washed four times with a washing solution containing 10 mM phosphate buffer, 150 mM sodium chloride, and 0.1% detergent (Tween 20).
  • a conjugate was prepared from rabbit anti-human prostatic acid phosphatase (Miles) and alkaline phosphatase by incubation in phosphate buffered saline pH 7.2(PBS), containing 0.1% (v/v) glutaraldehyde at 20°C for 4 hours. The conjugate was then diluted into PBS containing 0.1% BSA and 1 mM MgC12. Aliquots of this solution were added to a buffer containing PBS, 1 mM MgCl 2 , and test additives as shown in Table 2, at four concentration levels for each test additives. Thus, 4 test solutions were provided for each of the five additives and a control containing no additives.
  • Example 2 was repeated using Triton X-705 detergent and Tween 20 detergent as additives.
  • Triton X-705 gave a decrease in non-specific binding similar or better to that shown by Triton X-405.
  • the results obtained using Tween 20 were similar to those obtained using Triton X-100, ie.little or no reduction in non-specific binding.
  • Example 2 illustrates the use of Triton X - 405 detergent in the preparation of the micro plate, and illustrates a reduction in non-specific binding similar to that obtained in Example 2.
  • a plate was prepared in a similar manner to the plate of Example 2. Twenty minutes before the plate was used, 0.1 ml of a 5% v/v aqueous solution of Triton X-405 was introduced into the wells. The plate was allowed to stand for 20 minutes at 20°C, and the excess was aspirated. A conjugate as in Example 2 (containing no additive) was added to the wells, and incubated for réelle at 20°C. The plate was then washed four times with a phosphate/ saline buffer as in Example 2, and colorometric measurement was carried out as in Example 2. A control experiment was also provided with no pre-incubation with Triton X-405. The results are as shown in Table 3.
  • Test solutions containing a conjugate as in Example 2 and different concentrations of Triton X-405 was prepared as in Example 2. The test solutions were allowed to stand for 1 hour, and thereafter 40 micro litre aliquots each containing 80 ng of conjugate were added to wells of a clean uncoated nunc polystyrene test plate. The plate was incubated for lhr, washed three times with PBS, and the amount of conjugate bound to the plate was then measured as in Example 1. Since no protein had previously been bound to the plate, this is a measure of the extent to which Triton X-405 affects non-specific binding of a conjugate to polystyrene, rather than to protein bound to the plate. The absorbance and noise values obtained for the various concentrations are shown in Table 4.
  • Example 1 The effectiveness of various detergents in reducing noise in an assay as in Example 1 was assessed.
  • a polystyrene test plate was prepared as in Example 1, and immunoassays carried out in accordance with the general method described above.
  • the conjugate solution also contained 400mM ammonium sulphate.
  • a Linbro polystyrene microtitre plate was coated with cholera toxin by overnight incubation with toxin solutions of different combinations in carbonate buffer. The plate was emptied and the wells were washed three times with .25ml of a solution containing 5% (w/v) lactose, 0.5% (w/v) BSA, 0.1% Triton X705, pH 7.5.
  • An anti-toxin antibody standard was prepared by adding 0.01ml of commercial rabbit anti-toxin antibody to 10ml of a standard buffer containing Tris/HCl, pH 7.5, 50mM; 3% (w/v) BSA; 0.1% Triton X705.
  • Table 6B shows the resulting signal to noise ratio at different toxin coating concentrations with and without SB14 added.
  • Detection of progesterone in milk can be used as a marker for oestrus in cattle.
  • the milk contains large amounts of alkaline phosphatase which binds non-specifically to polystyrene surfaces. This Example illustrates that such non-specific binding may be lowered using the method of the invention.
  • a conjugate was prepared of 17 alpha-hydroxy progesterone and alkaline phosphatase. Samples were prepared of the conjugate and various additives as shown in Table 7. SB-12 and SB-16 are the dodecyl and hexadecyl homologues of SB-14.
  • SB 12 and SB 16 and, to an even greater extent, SB-14 are clearly capable of preventing contaminating alkaline phosphatase binding to a polystyrene surface. They thus reduce noise in an ELISA system for measuring progesterone in milk.
  • test kit comprising a test plate and bottles containing the following:
  • the coated plate was prepared as in Example 1, except that the antibody was a monoclonal antibody against TSH (Serono, D49 2 mg/1) and the washing solution contained degraded gelatine (a solution of 0.5% BYCO (CRODA GELATIN), 0.05% TWEEN 20, and 0.01% thiomersal) in place of BSA.
  • the plate was sealed in a foil bag containing a silica gel desiccant.
  • the TSH concentrations of 42 human serum samples were measured as follows:-
  • Biotinylated DNA was prepared using a Nick Translation Kit (EnZO Biochem Inc.) according to the manufacturer's instructions. Amounts of the biotinylated DNA as shown in Table 8 were transferred to discs (about 5.5mm diameter) of nitrocellulose (Schleicer and Schull) and incubated for 2 hours at 80°C. An avidin-alkaline phosphatase conjugate (Sigma Chemical Company) was used to measure the amount of biotinylated DNA on the filters as follows:
  • Table 8 shows the absorbances obtained after removing the discs and subtracting the reagent blank.
  • SB-16 greatly reduces the non-specific binding of alkaline phosphatase/avidin conjugate to nitrocellulose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
  • Automatic Analysis And Handling Materials Therefor (AREA)
EP84304328A 1983-06-30 1984-06-26 Biochemische Bestimmungsmethode und Testkasten zum Gebrauch hierfür Expired - Lifetime EP0132948B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT84304328T ATE62751T1 (de) 1983-06-30 1984-06-26 Biochemische bestimmungsmethode und testkasten zum gebrauch hierfuer.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8317855 1983-06-30
GB838317855A GB8317855D0 (en) 1983-06-30 1983-06-30 Biochemical detection method

Publications (2)

Publication Number Publication Date
EP0132948A1 true EP0132948A1 (de) 1985-02-13
EP0132948B1 EP0132948B1 (de) 1991-04-17

Family

ID=10545085

Family Applications (1)

Application Number Title Priority Date Filing Date
EP84304328A Expired - Lifetime EP0132948B1 (de) 1983-06-30 1984-06-26 Biochemische Bestimmungsmethode und Testkasten zum Gebrauch hierfür

Country Status (6)

Country Link
US (1) US4668639A (de)
EP (1) EP0132948B1 (de)
JP (1) JPS6036964A (de)
AT (1) ATE62751T1 (de)
DE (1) DE3484453D1 (de)
GB (1) GB8317855D0 (de)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0215457A3 (en) * 1985-09-12 1987-09-09 Boehringer Mannheim Gmbh Method for the determination of a partner of an immuno-reaction
EP0133272A3 (en) * 1983-07-30 1987-12-02 Boehringer Mannheim Gmbh Method for the determination of a partner of an immunological reaction and reagents for performing the method
EP0292809A3 (en) * 1987-05-23 1989-11-23 Behringwerke Aktiengesellschaft Method and composition for the determination of proteins
WO1990010232A1 (en) * 1989-03-01 1990-09-07 Eastman Kodak Company Composition containing labeled streptococcal antibody, test kit and assay using same
EP0363090A3 (de) * 1988-10-07 1991-07-17 Johnson & Johnson Clinical Diagnostics, Inc. Diagnostischer Testsatz und Verfahren zur Bestimmung von chlamydialen oder gonokokkalen Antigenen mit Gebrauch einer mikroporösen Membran
EP0363108A3 (de) * 1988-10-07 1991-07-17 EASTMAN KODAK COMPANY (a New Jersey corporation) Eine kationische Detergens enthaltende Waschlösung und deren Verwendung in chlamydialen und gonokokkalen Bestimmungen
US5047326A (en) * 1988-10-07 1991-09-10 Eastman Kodak Company Immunmological reagent composition and its use in the determination of chlamydial or gonococcal antigens
AU635355B2 (en) * 1989-11-02 1993-03-18 Teijin Limited Immunoassay of human thrombomodulin, and reagent and kit therefor
WO1994015951A1 (en) * 1993-01-14 1994-07-21 Bo Gustav Mattiasson Affinity purification by the use of a complexed ligand
US5360717A (en) * 1988-03-08 1994-11-01 Behringwerke Aktiengesellschaft Agent, for immunochemical assays, containing amine oxides
EP0857974A1 (de) * 1997-02-11 1998-08-12 Biolab Gmbh Schnelltest zur Progesteronbestimmung in Milch
US6066455A (en) * 1992-04-15 2000-05-23 Roche Diagnostics Gmbh Method of detecting nucleic acids

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151266A (en) * 1985-08-20 1992-09-29 Neorx Corporation Use of anionic detergents with conjugates of monoclonal or polyclonal antibodies
US5017474A (en) * 1988-02-12 1991-05-21 Eastman Kodak Company Wash solution, test kit and method for the determination of an immunological ligand
US4965191A (en) * 1988-02-12 1990-10-23 Eastman Kodak Company Lower alcohol sulfate wash solution, test kit and method for the determination of an immunological ligand
US5202267A (en) * 1988-04-04 1993-04-13 Hygeia Sciences, Inc. Sol capture immunoassay kit and procedure
US5077198A (en) * 1988-04-14 1991-12-31 Eastman Kodak Company Diagnostic kit and method for rapid detection of antibodies
JP2569383B2 (ja) * 1989-01-19 1997-01-08 帝人株式会社 免疫学的測定方法、試薬及びキツト
JP2561753B2 (ja) * 1989-10-02 1996-12-11 帝人株式会社 ヒト組織プラスミノーゲンアクチベーター・ヒトプラスミノーゲンアクチベーター複合体の免疫学的測定キツト及び測定方法
EP0450086A4 (en) * 1989-10-02 1993-03-10 Teijin Limited Kit for immunoassay of human tissue plasminogen activator/human plasminogen activator inhibitor complex and method of immunoassay
JP2509001B2 (ja) * 1989-11-02 1996-06-19 帝人株式会社 ヒト・トロンボモジユリンの免疫学的測定方法、そのための試薬及びそのためのキツト
US5194469A (en) * 1991-02-28 1993-03-16 The Goodyear Tire & Rubber Company Latex for coatings having improved flexibility
US5639626A (en) * 1994-11-15 1997-06-17 Chiron Diagnostics Corporation Reagents for specific binding assays
ATE412904T1 (de) * 1998-07-30 2008-11-15 Advanced Life Science Inst Inc Verfahren zur bestimmung von hepatitis c viren
US8796370B2 (en) * 2007-08-10 2014-08-05 Daikin Industries, Ltd. Coating composition
US20090104634A1 (en) * 2007-10-21 2009-04-23 Abbott Laboratories One-step immunoassays exhibiting increased sensitivity and specificity
JP5601075B2 (ja) * 2010-08-04 2014-10-08 株式会社リコー インクジェット用インク、並びにインクカートリッジ、インクジェット記録方法、インクジェット記録装置及びインク記録物
KR102291723B1 (ko) * 2020-01-15 2021-08-20 재단법인대구경북과학기술원 면역 블롯팅용 블로킹 조성물 및 이의 용도
CN117074657A (zh) * 2023-08-18 2023-11-17 安徽环球基因科技有限公司 一种elisa包被液

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148869A (en) * 1975-03-06 1979-04-10 Baxter Travenol Laboratories, Inc. Immunological reagent and method of using same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5443572B2 (de) * 1974-07-08 1979-12-20
IL48804A (en) * 1975-01-29 1979-05-31 Baxter Travenol Lab Imminological reagent comprising a mixture of polyethyleneglycol and a nonionic surfactant
US4256724A (en) * 1978-02-21 1981-03-17 Becton, Dickinson And Company Method for non-covalent coating of antibodies on solid substrates
JPS5925184B2 (ja) * 1978-12-22 1984-06-15 天野製薬株式会社 免疫測定法における非特異的阻害作用の除去法
JPS5642142A (en) * 1979-08-31 1981-04-20 Amano Pharmaceut Co Ltd Removing method for nonspecific reaction inhibiting action in immunity measuring method
US4319882A (en) * 1980-02-21 1982-03-16 Yash Sharma Method for detecting immunological agglutination and biochemical agent therefor
JPS57132252A (en) * 1981-02-09 1982-08-16 Hitachi Ltd Fault discrimination system
JPS5923252A (ja) * 1982-07-30 1984-02-06 Fuji Photo Film Co Ltd チロキシンの蛍光測定もしくは比色による定量分析法
JPS5997057A (ja) * 1982-11-26 1984-06-04 Kainosu:Kk 抗血清試薬

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148869A (en) * 1975-03-06 1979-04-10 Baxter Travenol Laboratories, Inc. Immunological reagent and method of using same

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0133272A3 (en) * 1983-07-30 1987-12-02 Boehringer Mannheim Gmbh Method for the determination of a partner of an immunological reaction and reagents for performing the method
EP0215457A3 (en) * 1985-09-12 1987-09-09 Boehringer Mannheim Gmbh Method for the determination of a partner of an immuno-reaction
EP0292809A3 (en) * 1987-05-23 1989-11-23 Behringwerke Aktiengesellschaft Method and composition for the determination of proteins
US5360717A (en) * 1988-03-08 1994-11-01 Behringwerke Aktiengesellschaft Agent, for immunochemical assays, containing amine oxides
EP0363090A3 (de) * 1988-10-07 1991-07-17 Johnson & Johnson Clinical Diagnostics, Inc. Diagnostischer Testsatz und Verfahren zur Bestimmung von chlamydialen oder gonokokkalen Antigenen mit Gebrauch einer mikroporösen Membran
EP0363108A3 (de) * 1988-10-07 1991-07-17 EASTMAN KODAK COMPANY (a New Jersey corporation) Eine kationische Detergens enthaltende Waschlösung und deren Verwendung in chlamydialen und gonokokkalen Bestimmungen
US5047326A (en) * 1988-10-07 1991-09-10 Eastman Kodak Company Immunmological reagent composition and its use in the determination of chlamydial or gonococcal antigens
WO1990010232A1 (en) * 1989-03-01 1990-09-07 Eastman Kodak Company Composition containing labeled streptococcal antibody, test kit and assay using same
AU635355B2 (en) * 1989-11-02 1993-03-18 Teijin Limited Immunoassay of human thrombomodulin, and reagent and kit therefor
US6066455A (en) * 1992-04-15 2000-05-23 Roche Diagnostics Gmbh Method of detecting nucleic acids
WO1994015951A1 (en) * 1993-01-14 1994-07-21 Bo Gustav Mattiasson Affinity purification by the use of a complexed ligand
EP0857974A1 (de) * 1997-02-11 1998-08-12 Biolab Gmbh Schnelltest zur Progesteronbestimmung in Milch

Also Published As

Publication number Publication date
GB8317855D0 (en) 1983-08-03
EP0132948B1 (de) 1991-04-17
DE3484453D1 (de) 1991-05-23
JPS6036964A (ja) 1985-02-26
ATE62751T1 (de) 1991-05-15
US4668639A (en) 1987-05-26

Similar Documents

Publication Publication Date Title
EP0132948B1 (de) Biochemische Bestimmungsmethode und Testkasten zum Gebrauch hierfür
EP0347138B1 (de) Spezifische Bindungszusammensetzung mit einem Protein oder einem Kohlenhydrat mit Nieder-pI und ein diagnostischer Testsatz und Verfahren zur Anwendung
EP0444302B1 (de) Immunoassay-Verfahren einschliesslich Deaktivierung von endogener alkalischer Phosphatase
EP0014530B1 (de) Verfahren zum Nachweis und zur Bestimmung spezifisch bindender Proteinsubstanzen und mit diesen Substanzen bindbarer Materialien, Testzusammensetzung und Reagenziensatz dafür
US4870007A (en) Immobilized biotinylated receptor in test device, kit and method for determining a ligand
JP2588274B2 (ja) 定性酵素アッセイの視覚的識別
EP0124352A2 (de) Geschützter Bindungstest
EP0315364A2 (de) Gleichzeitiger Immunassay zur Bestimmung von Antigenen und Antikörpern
JPH0239747B2 (de)
JPH0346561A (ja) 分析物検出のための方法、試薬及び試験ストリップ
CA1084394A (en) Extraction-free cortisol assay
EP0369362B1 (de) Substrat-Zusammensetzung für Alkali-Phosphatase sowie ihre Verwendung bei Testverfahren
US5188938A (en) Enzyme quantitation wicking assay
US6242265B1 (en) Use of doubly or triply charged cations in immunochemical assays
EP0363108A2 (de) Eine kationische Detergens enthaltende Waschlösung und deren Verwendung in chlamydialen und gonokokkalen Bestimmungen
CA1335173C (en) Solid-phase non-separation enzyme assay
US5093231A (en) Substrate composition for alkaline phosphatase and method for assay using same
US5470711A (en) Saliva enhancement reagent for feline leukemia virus elisa
EP0529057B1 (de) Denaturierte transportproteine zur verbesserung von enzymgebundenen immunoassays (elisa)
US5294535A (en) Method for suppressing partial coloration in immunoassays utilizing peroxidase labels
EP0301333A2 (de) Auf liposomen basierter, homogener Immunoassay für diagnostische Teste
EP0376707B1 (de) Enzym-Quantifizierungstest auf einem Docht
EP0184701A2 (de) Verfahren zur Bestimmung eines Liganden

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19850719

17Q First examination report despatched

Effective date: 19861110

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

ITF It: translation for a ep patent filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Effective date: 19910417

REF Corresponds to:

Ref document number: 62751

Country of ref document: AT

Date of ref document: 19910515

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3484453

Country of ref document: DE

Date of ref document: 19910523

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
EPTA Lu: last paid annual fee
EAL Se: european patent in force in sweden

Ref document number: 84304328.2

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19950601

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19950626

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19950629

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19950710

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19950929

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19960626

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19960627

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19960628

Year of fee payment: 13

Ref country code: DE

Payment date: 19960628

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19960630

Ref country code: CH

Effective date: 19960630

Ref country code: BE

Effective date: 19960630

BERE Be: lapsed

Owner name: IQ (BIO) LTD

Effective date: 19960630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19970101

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

EUG Se: european patent has lapsed

Ref document number: 84304328.2

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 19970101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19980227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19980303

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19990517

Year of fee payment: 16

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000626

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20000626